Project 1 - TGF-beta1 directly modulates excitation-contraction signaling in airway smooth muscle to evoke airway hyperresponsiveness in asthma
项目 1 - TGF-β1 直接调节气道平滑肌中的兴奋收缩信号传导以引起哮喘气道高反应性
基本信息
- 批准号:10465060
- 负责人:
- 金额:$ 51.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-07-15 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAgonistAsthmaBindingBronchoconstrictionBronchodilationCalciumCellsCharacteristicsCoinCollaborationsCouplingCytometryCytoskeletonDataDiseaseExposure toFunctional disorderG ActinG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsGenerationsGoalsHumanInflammationInterleukin-13LungMagnetismMeasuresMediatingMicroscopyModelingMolecularMuscle ContractionMyosin Light ChainsPathogenesisPathway interactionsPatternPhenotypePhosphatidylinositolsPhosphorylationPhosphotransferasesPlayProcessProteinsROCK1 geneRegulationReportingRho-associated kinaseRoleSeveritiesSignal PathwaySignal TransductionSliceSmad ProteinsSmall Interfering RNASmooth Muscle MyocytesTGFB1 geneTechniquesTestingTransforming Growth Factor betaTransforming Growth FactorsViralairway hyperresponsivenessairway obstructionairway remodelingalpha Actinasthma exacerbationcofilinhuman modelinhibitorinjured airwayinjury and repairknock-downlatrunculin Amyosin phosphatasenew therapeutic targetnovelpolymerizationpreventrespiratory smooth muscleresponse
项目摘要
Project Summary
Frequent exacerbations induce airway injury and remodeling, and define the severity of asthma. Severe asthma
also manifests as a phenotype with irreversible airway obstruction. However, the role of airway remodeling in the
pathogenesis of irreversible airway obstruction remains controversial. Transforming growth factor β1 (TGF-β1)
plays a pivotal role in orchestrating airway remodeling; whether TGF-β1 modulates human airway smooth muscle
(HASM) shortening and airway hyperresponsiveness (AHR) is unknown. We recently discovered that TGF-β1
alone evokes contraction and augments agonist-induced shortening of HASM, the pivotal cell regulating
bronchomotor tone. Our overarching goal is to define the molecular transduction processes that regulate
TGF-β1 effects on HASM excitation-contraction (EC) coupling in asthma. We have shown that contractile
agonists evoked HASM shortening by activating G12, RhoA, PI3Kδ and Rho kinase. Whether these processes
mediate TGF-β1 effects on EC coupling remain unknown. We posit a central hypothesis that TGF-β1
modulates HASM shortening by activating PI3Kδ, Rho Kinase and RhoA-dependent actin polymerization
in asthma. To test this hypothesis, we developed novel techniques of single cell force generation, human
precision cut lung slices (hPCLS), targeted protein knockdown and, human models of AHR. In Aim 1, we will
define whether TGF-β1 increases bronchomotor tone and augments agonist-induced HASM shortening in a
PI3Kδ-/Rho kinase-dependent manner. Using asthma- and non-asthma-derived HASM cells and hPCLS,
disease-state effects on TGF-β1-induced activation of PI3Kδ and Rho Kinase will be determined. The role of
Smad proteins in mediating TGF-β1-induced single cell contraction and AHR will be characterized after Smad3/4
knockdown. In Aim 2, we will determine whether G12 and RhoA depletion modulates activation of RhoA, PI3Kδ,
ROCK activity and HASM shortening after TGF-β1 exposure. In Aim 3, we will explore whether actin dynamics
mediates TGF-β1 effects on HASM contraction. Phosphorylation levels of cofilin and filamentous/globular actin
ratios, key modulators of actin polymerization, will be measured in the presence and absence of latrunculin A (an
actin disruptor) or siRNA to cofilin. In collaboration with Project 3, Cores A, and B, we will characterize the pivotal
signaling pathways mediating the effects of TGF-β1 on bronchomotor tone and AHR, and identify novel
therapeutic targets and molecules to prevent or abrogate these effects, which are characteristically observed after
asthma exacerbations and/or in severe asthma.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Reynold Alexander Panettieri其他文献
Reynold Alexander Panettieri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Reynold Alexander Panettieri', 18)}}的其他基金
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10260091 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma
新型分子机制促进 GPCR 诱导的哮喘支气管扩张
- 批准号:
10478318 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Novel Molecular Mechanisms Promote GPCR-Induced Bronchodilation in Asthma
新型分子机制促进 GPCR 诱导的哮喘支气管扩张
- 批准号:
10271810 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
9890029 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10582591 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10201004 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10360219 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10360671 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
New Jersey Alliance for Clinical Translational Science: NJ ACTS
新泽西临床转化科学联盟:NJ ACTS
- 批准号:
10115156 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPD
罕见变异和血统对哮喘和慢性阻塞性肺病 (COPD) β 受体激动剂反应的影响
- 批准号:
10533637 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPD
罕见变异和血统对哮喘和慢性阻塞性肺病 (COPD) β 受体激动剂反应的影响
- 批准号:
10620284 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10398799 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10084583 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
胰高血糖素样肽 1 受体激动剂治疗成人肥胖相关症状性哮喘
- 批准号:
10609049 - 财政年份:2021
- 资助金额:
$ 51.51万 - 项目类别:
Effects of Rare Variants and Ancestry on Beta Agonist Response in Asthma and COPD
罕见变异和血统对哮喘和慢性阻塞性肺病 (COPD) β 受体激动剂反应的影响
- 批准号:
10078976 - 财政年份:2019
- 资助金额:
$ 51.51万 - 项目类别:
Molecular mechanisms underlying the clinical efficacy of inhaled corticosteroid/long-acting beta2-adrenoceptor agonist combination therapies in asthma
吸入皮质类固醇/长效β2-肾上腺素受体激动剂联合疗法治疗哮喘临床疗效的分子机制
- 批准号:
369425 - 财政年份:2017
- 资助金额:
$ 51.51万 - 项目类别:
Operating Grants
Molecular mechanisms underlying the enhanced efficacy of inhaled corticosteroid/long-acting beta2-adrenoceptor agonist combinations used in asthma
吸入皮质类固醇/长效β2-肾上腺素受体激动剂组合增强哮喘疗效的分子机制
- 批准号:
366550 - 财政年份:2016
- 资助金额:
$ 51.51万 - 项目类别:
Operating Grants
Effects of Rare Variants and Ancestry on Beta Agonist Response In Asthma
罕见变异和祖先对哮喘β受体激动剂反应的影响
- 批准号:
9098841 - 财政年份:2015
- 资助金额:
$ 51.51万 - 项目类别:
Effects of Rare Variants and Ancestry on Beta Agonist Response In Asthma
罕见变异和祖先对哮喘β受体激动剂反应的影响
- 批准号:
8968045 - 财政年份:2015
- 资助金额:
$ 51.51万 - 项目类别:














{{item.name}}会员




